First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide by Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma‐Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie‐Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, K. Rajender Reddy

Get full text